CEBPA Mutation Analysis

Last Modified: 8/31/2023 3:16:14 PM


Medical Necessity Documentation:  
Client Notes:  
Patient Preparation:  
Specimen Requirements: 5.0 mL Whole Blood in a Lavender Top Tube(s) - EDTA
Collection Instructions:  
Minimum Volume: 2.0 mL
Transport & Storage: Temperature/Stability:

7 days Ambient
7 days Refrigerated
Rejection Criteria: Frozen; Gross Hemoloysis
Reference Range: Not detected
Critical Ranges:  
Test Comments:  
Methodology: Polymerase Chain Reaction (PCR)
Clinical Significance:

The CEBPA gene, a myeloid transcription factor, is mutated in a subset of acute myeloid leukemia (AML), particularly those with chromosome analyses showing normal diploid karyotype, Cytogenetically Normal (CN). CN-AML that have CEBPA mutations show favorable outcome compared to other groups of CN-AML.
Testing for CEBPA mutation, along with NPM1 (test code 16158-NPM (Exon 12) Mutation Analysis, Cell-based) is recommended for all patients with CN-AML.
Documentation:  
Custom Panel: No

PRODUCTION SCHEDULE

Turn Around Time: 3 to 6 days
Days Performed: Tuesday, Thursday, Saturday
Sites Performed: Quest - Chantilly to San Juan Capistrano
PHL Test Code: CEBP
EPIC Test Code: LAB3050
Send Out Test Code: 90812
Included Tests:  
CPT Coding: 81218

Go back to the top of the page.